FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
0:00
4:00
Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
Weitere Episoden von „FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)“
Verpasse keine Episode von “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” und abonniere ihn in der kostenlosen GetPodcast App.